Powered 500 · 2026POWEREDS. 299 of 500
Haviland steered Blueprint Medicines through the transition most precision medicine companies never survive, commercializing Ayvakit into one of biotechnology's most successful rare disease products while advancing a deep pipeline of additional genomically targeted therapies.
Kate Haviland is the former President and CEO of Blueprint Medicines, the precision therapy company she led to commercialize Ayvakit and other targeted medicines for cancers and rare genetic diseases.
Sanofi acquired Blueprint Medicines, where Haviland had risen from COO to CEO, and she was named the 2025 EY Entrepreneur of the Year National Life Sciences Award winner for her operational execution in bringing precision medicines to patients.
Interview · In Pipeline
Sponsored placement
An invitation, extended to Powered readers.
Drive the Continental GT S.
Request a test driveBentley T&Cs apply
